Cor Therapeutics Inc. (CORR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert Mayo who wrote (320)	1/13/1999 4:41:00 PM
From: aknahow	Read Replies (3) of 712

More news, agreement to screen 5 compounds for potential development. biz.yahoo.com ALSO from splendid article by Eisinger at thestreet.com Cor's Kailian was similarly forgetful. Cor's drug Integrilin, a competitor to market dominant ReoPro, has had a severely disappointing launch. That could explain Kailian's lengthy treatment of the dynamics of heart-attack care, to the exclusion of detail and projections about Cor's financials. The CEO did say Integrilin has reached a rate of around $700,000 in sales a week, which is rising. The Street's expectation is that the company will report $10 million in sales for the most recent quarter, and it should hit that. But are expectations still too high for this year? Many investors think so. In other parts of the conference article he mentions Cor's presentation as boring, in that a lot of it was devoted to how one treats someone having a heart attack. Remember they over used this educitation them IMO in their annual report also. BTW don't get upset with the Eisinger comments. This is the sort of stuff I like to see and I hope management pays attention to.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next